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Abstract
Background: Chikungunya virus (CHIKV) is a major 
threat to Australia given the distribution of competent 
vectors, and the large number of travellers return-
ing from endemic regions. We describe current 
knowledge of CHIKV importations into Australia, 
and quantify reported viraemic cases, with the aim 
of facilitating the formulation of public health policy 
and ensuring maintenance of blood safety.
Methods: Cases reported to the National 
Notifiable Disease Surveillance System (NNDSS) 
from 2002 to 2012 were analysed by place, 
month of acquisition, and place of residence. 
Rates of chikungunya importation were estimated 
based on reported cases and on the numbers of 
short-term movements.
Results: Between 2002 and 2012, there were 168 
cases of chikungunya virus (CHIKV) imported into 
Australia. Victoria and New South Wales had 
the largest number of notifications. The main 
sources were Indonesia, India and Malaysia. The 
number of cases increased from 2008 to reach a 
peak in 2010 (n=64; 40%). Although Indonesia 
accounted for the majority of CHIKV notifications 
in Australia, travel from India had the highest 
CHIKV importation rate (number of imported 
cases per 100,000 travellers).
Conclusions: The Australian population is increas-
ingly at risk from CHIKV. Arrivals from endemic 
countries have increased concurrently with vec-
tor incursions via imported goods, as well as via 
local movement from the Torres Strait to North 
Queensland ports. An outbreak of CHIKV could 
have a significant impact on health, the safety of 
the blood supply and on tourism. Case and vector 
surveillance as well as population health responses 
are crucial for minimising any potential impact of 
CHIKV establishment in Australia.
Keywords: Chikungunya, importation, risk, 
travellers, Australia, vectors, viraemic cases
Introduction
Chikungunya virus (CHIKV) is a mosquito-borne 
Alphavirus of the family Togaviridae. The virus is 
endemic in Africa, India, South-East Asia and the 
Western Pacific and is considered to be emerging or 
re-emerging in many regions of the world.1-4 The 
disease was first detected in 1952 in Africa follow-
ing an outbreak on the Makonde Plateau.5,6 The 
name chikungunya is derived from the Makonde* 
root verb, meaning “to become contorted” or “that 
which bends up” in reference to the stooped pos-
ture developed when arthritic symptoms appear. 
The virus was originally observed in Central and 
East Africa, circulating in a sylvatic cycle between 
forest-dwelling mosquitoes, non-human primates,4,7 
with sporadic human cases. In urban centres of 
Africa and throughout Asia, CHIKV is transmitted 
from viraemic humans via mosquitoes to avail-
able non-immune human hosts.8 Although it is not 
demonstrated that cross-protection after infection 
with other alphaviruses (Ross River—RRV, O’nyong 
nyong—ONNV viruses) occurs in humans, it has 
been shown in animal models.9-12 Large outbreaks 
of CHIKV have become more frequent in many 
endemic regions, including a number of Indian 
Ocean and Pacific Island nations, including Papua 
New Guinea, as well as emergent cases in histori-
cally non-endemic areas, such as Italy.13,14,15
These outbreaks have led to considerable problems 
for public health authorities, not only in relation to 
adequate vector control and epidemiological sur-
veillance but also on the sustainability of the blood 
supply.16,17 For example, in La Réunion Island in 
2005, in which more than 30% of the population was 
infected during an outbreak, local blood donation 
was suspended to prevent transfusion-transmitted 
infection and pathogen inactivation was introduced 
to avoid critical shortages in platelet components.16
Potential Australian CHIKV vectors include; Aedes 
vigilax, Aedes procax, Coquillettidia linealis, and 
Aedes notoscriptus [all competent RRV and Barmah 
Forest virus (BFV) vectors] as well as Aedes aegypti 
and Aedes albopictus.18,19 However, except for the last 
two, transmission is unlikely due to limited contact 
between these vectors and people.18 Currently, Ae. 
aegypti is distributed widely throughout northern and 
central Queensland, with Goomeri (235 km north 
of Brisbane) the southern limit near the coast and 
 
*  The Makonde Plateau is a border area between Tanzania 
and Mozambique. “Chikungunya” is from the Makonde 
language.
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Charleville (740km north west of Brisbane) the south 
western limit.20,21 Ae. albopictus is currently restricted 
to the Torres Strait Islands off Cape York.22,23 However 
incursions of this species, which is a more cold-
tolerant mosquito than Ae. aegypti, do occur. In India, 
during an outbreak in 2005-06, Ae. aegypti was the 
main vector associated with disease transmission.24 
However, in the Indian Ocean CHIKV outbreak 
in 2005-2006, a mutation in the virus increased the 
transmission ability of Ae. albopictus.25 Because this 
mosquito can survive in temperate climates, it has 
become a worldwide concern as a CHIKV vector.
The genus Alphavirus contains seven antigenic 
complexes. CHIKV belongs in a complex with 
ONNV, BFV, Semliki Forest (SFV), RRV, Sindbis 
(SINV), and Mayaro viruses (MAYV); members 
of the complex cause rheumatic manifestations 
including arthralgia.26,27 For CHIKV infections 
the extrinsic incubation period (EIP) appears to 
be short in Ae. albopictus, as little as two days after 
the infective blood meal.28 However, the EIP can 
be as long as 15 days when taken as time to reach 
maximum transmission efficiency.29  The intrinsic 
incubation period ranges from 1 to 12 days (typi-
cally 2–4 days).13 This period is followed by sudden 
onset of high fever, severe myalgia and arthralgia, 
with headaches, a skin rash and photophobia.15,30,31 
The symptoms usually resolve within 1-2 weeks 
but arthralgia may persist for weeks or months fol-
lowing the acute illness.27 Infections may rarely be 
complicated by encephalopathy and hepatic fail-
ure.30 CHIKV can also be transmitted to neonates 
by vertical transmission.32,33 During recent epidem-
ics in the Indian Ocean region, maternal-foetal 
transmission, severe neonatal disease, and adult 
mortality were reported.34,35
CHIKV infection is diagnosed on the basis of clini-
cal and epidemiological criteria and can easily be 
confused with disease caused by other alphaviruses 
such as SINV, RRV and BFV, as well as dengue virus 
infection (Flavivirus) and hence requires laboratory 
confirmation. The most commonly used methods 
for laboratory diagnosis are serological tests and the 
quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) that detects the presence of 
viral RNA in serum.36,37
In Australia, the principal CHIKV vectors are 
present in suitable environments near susceptible 
populations. In addition, countries endemic for 
CHIKV are frequently visited by tourists, which 
eventually may result in chikungunya infec-
tious cases in visitors or residents returning to 
Australia.38-41 At present, the risk of CHIKV becom-
ing established in Australia is restricted to areas 
where the vectors are present in sufficient density 
(Torres Strait Islands for Ae. albopictus and North 
Queensland for Ae. aegypti). CHIKV transmission 
in Queensland and the Torres Strait islands would 
have significant population health implications, 
including a potential impact on the supply of fresh 
blood components. In this study, we undertook 
an analysis of imported CHIKV cases in order to 
understand importation pathways and assess the 
risk of chikungunya emergence in Australia.
Methods
Chikungunya surveillance system
Chikungunya is notifiable in all Australian States and 
Territories except the Australian Capital Territory. It is 
not currently nationally notifiable, but a national case 
definition was implemented in 2010, and Australia’s 
National Notifiable Diseases Surveillance System 
(NNDSS) includes a separate disease category for 
chikungunya. Before 2010, cases of chikungunya were 
sent to the NNDSS under the disease group “arbovirus 
Not Elsewhere Classified (NEC)” and the Northern 
Territory still maintains this practice.
Case definition
Under the Communicable Diseases Network Australia 
(CDNA) surveillance case definition for CHIKV, a 
confirmed case requires definitive laboratory evidence 
before notification.42 Definitive laboratory evidence is: 
•	 isolation of CHIKV
•	 detection of the virus by nucleic acid testing
•	 seroconversion or a significant rise in antibody 
level to chikungunya virus, in the absence of 
a corresponding change in antibody levels to 
RRV and BFV or 
•	 detection of CHIKV-specific IgM, in the 
absence of IgM to RRV and BFV.
If the suspected case has not travelled to an endemic 
or epidemic country, then confirmation by a second 
reference laboratory is required.
Data collection
Notification data
Data on notifications of CHIKV infection were 
extracted from the NNDSS (8 February 2013). 
These data were subject to retrospective revision and 
may vary from that reported in published NNDSS 
reports and reports of notification data by states 
and territories. Notifications of chikungunya under 
“arbovirus NEC” were included. ‘Diagnosis date 
(month and year of diagnosis)’ represents the onset 
date, or where the date of onset was not known, the 
earliest of specimen collection date, notification 
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date, or date notification was received. Data span 
1 January 2002 to 31 December 2012. ‘Place of 
acquisition’ was based on where the infection was 
believed to have been acquired, and the incubation 
period and time spent in a location or the place of 
recent travel. Data on place of acquisition were 
obtained from the NNDSS, and checked (up to 30 
June 2011) and completed by State and Territory 
data managers for National Arbovirus and Malaria 
Advisory Committee (NAMAC) annual reports. 
Where insufficient information was available on 
the country or region of acquisition, ‘Overseas – 
unknown/inadequately described’ was recorded. 
Place of acquisition is usually obtained through pub-
lic health follow-up of each case. ‘State/Territory’ is 
the state or territory of residence of the case. Cases 
residing in one jurisdiction but diagnosed in another 
are notified by the state of residence. Duration of 
travel was not recorded.
Overseas travel data
We accessed overseas arrivals and departures tables 
from the Australian Bureau of Statistics (ABS) 
website for 2008 to 2012.43 Earlier years were not 
analysed because there were fewer than five cases of 
CHIKV per year before 2008. We analysed the num-
ber of short-term movements (resident departures 
and visitor arrivals) from Indonesia, Malaysia and 
India, the three main sources of importation identi-
fied. Monthly data are complete from January 2008 
to December 2012 inclusive.
Data analysis
Short-term resident departures and visitor arrivals in 
Australia have been analysed for the study period.43 
Short-term resident departures (STRD) are defined 
as Australian residents intending to stay abroad 
for less than 12 months. Short-term visitor arrivals 
(STVA) are defined as overseas visitors intending to 
stay in Australia for less than 12 months. Short-term 
movement is defined as less than one year in duration.
The total and mean number of short-term movements 
(STRD and STVA) per year have been calculated for 
Indonesia, Malaysia and India, and were used to deter-
mine the percentage increase in these travel categories 
from 2008 to 2012. Importation rates based on short-
term resident departures alone, and short-term resident 
departures summed with visitor arrivals over the period 
2008 to 2012 have been calculated per 100,000 persons.
We used short-term movement information as these 
data include the country departed to or arrived from, 
whereas such information is not included with long-
term movement data. We selected short-term visitor 
arrivals (overseas visitors intending to stay less than 
one year), and STRD (Australian residents intend-
ing to stay abroad less than one year). STRD were 
used rather than returns, because short-term resident 
returns are not available by country. We assumed 
near equivalence of STRD and short-term resident 
returns. But short-term resident returns may be fewer 
than STRD if some people decide to stay longer than 
one year, or die overseas. We assumed that numbers 
in these categories (longer than intended stay and 
overseas deaths) would be low.
Results
Number of CHIKV notifications
Since 2002 there have been 168 CHIKV notifications 
in Australia, 160 of which were during the study 
period (2008 to 2012). There was no clear seasonal-
ity in importation rate, although importations were 
slightly more common in the period October to April 
(Figure 1). In 2010, case numbers were highest in 
October (14 cases, comprising 22% of notifications 
for the year). The number of cases peaked in 2010 
(n= 64) accounting for 40% of cases during the 
study period. In 2011 and 2012, 38 and 16 cases were 
reported, respectively.
Source of CHIKV importations
All CHIKV cases in Australia were acquired overseas. 
The three most common countries of acquisition 
were Indonesia (28.0%), India (18.5%), and Malaysia 
(10.0%) (Figure 2). The remaining 43.5% were from 
other countries, and of these 15.0% were unknown or 
inadequately described at the time of notification.
State of residence
Of the 160 cases, the majority (57.0%) returned to the 
two most populous states, Victoria and New South 
Wales (Table 1). Except for the Australian Capital 
Terrority, in which CHIKV is not notifiable, all states 
and territories reported cases. India and Indonesia 
respectively accounted for 26.0% and 24.0% of cases 
reported from Victoria and New South Wales.
Predicted number of imported cases based on 
short-term travel data
Over the study period, there was an increase in SDRD 
and STVA arrivals for the three main source countries 
for CHIKV infections (Figures 3 and 4). From 2008 
to 2012, the number of STRD to Indonesia increased 
(+140%) as did, to a lesser extent, departures from 
India (+57%) and Malaysia (+36%). The number of 
STVA also increased from 2008 to 2012 (+54% for 
Indonesia and Malaysia, +35% for India).
We utilised STRD as well as visitor arrival numbers, 
along with notification source data, to estimate 
CHIKV importation rates in travellers returning 
from Indonesia, India and Malaysia. Our analysis 
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Figure 1: Number of reported cases of CHIKV, 
2008 to 2012, by month and year
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Figure 2: Number of reported cases of CHIKV, 
2008 to 2012, by country of origin and year
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Table 1: Number of reported 
territory, 2008 to 2012
Country of acquisition
Indonesia
India
Malaysia
East Timor
Sri Lanka
Thailand
Vietnam
Bangladesh
Other countries*
Unknown/inadequately described
State/Territory
NSW NT QLD SA TAS VIC WA
11 8 5 0 1 11 11
9 0 2 0 0 15 4
5 0 3 0 1 4 4
0 4 0 0 0 4 1
0 0 0 1 0 3 0
0 0 1 1 0 4 0
1 0 0 0 0 1 1
3 0 0 0 0 0 0
5 1 2 1 0 6 2
5 0 2 6 0 4 7
cases of CHIKV infection by country of acquisition and state or 
Total
47
30
17
9
4
6
3
3
17
24
Total 39 13 15 9 2
* 12 countries constituting ‘Other countries’ were known sources of chikungunya infection.
52 30 160
Figure 3: Total number of STRD 
from Australia, visiting Indonesia, 
Malaysia and India, 2008 to 2012 
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Figure 4: Total number of STVA, visiting 
Indonesia, Malaysia and India, 2008 to 2012 
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Table 2: CHIKV importation rates per 100,000 passengers, 2008 to 2012, by country
Indonesia Malaysia India
n imported cases* 47 17 30
Total Passengers (STRD†) 3,458,100 1,180,600 855,600
CHIKV Import. Rates§ 1.35 1.43 3.50
Total Passengers (STRD + STVA‡) 4,071,500 2,304,000 1,541,500
CHIKV Import. Rates§ 1.15 0.73 1.94
* n imported cases: number of CHIKV imported cases
† STRD: Short-Term Resident Departures
§ CHIKV Import. Rates: Importation rates of chikungunya per 100,000 persons
‡ STVA: Short-Term Visitor Arrivals
suggests that, although Indonesia was the greatest 
source of infection acquisition, risk for CHIKV 
acquisition was highest for India (Table 2).
Discussion
Australia is at risk of local CHIKV transmission. 
Factors that determine Australia’s risk include an 
immunologically naïve population (unless cross-
protection with other alphaviruses occurs), regular 
introductions of the virus, presence of competent 
mosquito vectors, and an appropriate climate for 
exotic vectors. Climate change has the potential 
to increase vector range, as increased temperature 
and humidity could increase the areas in Australia 
receptive to vectors. The movement of workers and 
human behaviour might have an important role in 
emergence of CHIKV, as well as the introduction and 
establishment of Ae. albopictus. Indeed in Malaysia, 
migrant workers coming from endemic neighbour-
ing countries are suspected to be the major source 
for CHIKV re-emergence.30 Moreover, a recent 
study has shown that an increasing number of chi-
kungunya cases have been reported to the Ministry 
of Health of Malaysia and the country may become 
endemic for CHIKV.44 Due to the presence of Ae. 
aegypti and Ae. albopictus in the north of Australia, 
a local outbreak is likely to occur. Knowledge of 
vector competence of local mosquitoes is a starting 
point for understanding the risk of autochthonous 
transmission.18 It is important to predict population 
health response requirements on the basis of knowl-
edge of epidemic risk relative to number and timing 
of viraemic imports and relevant vector biology.
One hundred and sixty imported CHIKV cases 
were reported between 2008 and 2012. Under-
reporting, due either to misdiagnosis or asympto-
matic infection, is highly probable. Even for RRV, 
which is endemic, under-reporting is consider-
able.26 These data give an overview of viraemic 
importations over the last 5 years and enable 
assessment of the most important source coun-
tries. Fifty seven per cent of reported cases come 
from Indonesia, India and Malaysia, countries 
where CHIKV has recently re-emerged. There 
was no strict importation seasonality during the 
study period. The inclusion of 15% of cases with 
unknown or inadequately described source repre-
sents significant missing data in the NNDSS.
We utilised travel data, along with the sources of 
CHIKV notifications in Australia to identify the 
highest risk source countries. Although Indonesia 
accounted for the majority of CHIKV notifications 
in Australia, India had the highest CHIKV importa-
tion rate. Travel to India has been steadily increasing 
in recent years, although not as rapidly as travel to 
other countries and CHIKV cases in Australia may 
increase in the future if this trend continues. It is 
also noteworthy that rates of CHIKV infection in 
returning travellers from East Timor could be higher 
than rates for India, Malaysia and Indonesia, given 
the relatively small number of total arrivals from 
that country. However, the total infections acquired 
in East Timor accounted for a small percentage of 
cases (<6% of cases between 2008 and 2012).
Notwithstanding the efforts of state and territory 
health departments (notably the Northern Territory 
Health Department and Queensland Health) to 
successfully manage exotic mosquito-borne diseases 
and their vectors, 45,46 the introduction of exotic vec-
tors cannot be wholly prevented. It is likely that Ae. 
albopictus will become established on the Australian 
mainland.23 Although numerous detections of Ae. 
albopictus have been successfully managed without 
the establishment of this species as yet, incursions 
continue to occur. In recent times Ae. albopictus 
was detected near Melbourne (December 2012) 
and is the subject of an on-going surveillance and 
control program (S. Lynch, Victorian Department 
of Primary Industries, pers. comm. 20 Dec 2012). 
The mosquitoes entered via a consignment of lucky 
bamboo (Dracaena). In Australia, other mosquito 
species such as Ae. vigilax, Ae. procax, Ae. notoscrip-
tus and Cq. linealis,47-49 could potentially transmit 
CHIKV,18 although this is highly unlikely because of 
their behavior and ecology.
E140 CDI Vol 37 No 2 2013
Original articles 
CHIKV has re-emerged after two to four decades, in 
some countries e.g. after 39 years in the Democratic 
Republic of Congo, 32 years in India, and 20 years 
in Indonesia.51 In Southeast Asian endemic regions, 
where the original Asian genotype circulated for 
several decades, new strains belonging to the Indian 
Ocean Lineages (IOL) have emerged,52,53 and caused 
major outbreaks especially in Malaysia.53-57 The shift 
in viral genotypes is a major threat not only for the 
Asian region but also for the Western Pacific and 
Australia, where Ae. aegypti and Ae. albopictus are 
present in Queensland.
If local CHIKV transmission were to occur in 
Australia, this virus might cause considerable 
problems for public health authorities and impact 
on the nation’s blood supply. CHIKV presents a 
risk to transfusion safety. During an outbreak in 
La Réunion Island in 2005 in which 30% of the 
population were infected, local blood donation was 
suspended and pathogen reduction of platelet com-
ponents was implemented as an additional safety 
measure.16 Dengue is episodic in north Queensland. 
A recent study has demonstrated that local outbreaks 
pose a relatively high risk to the safety of Australia’s 
blood supply, with the large 2009 epidemic costing 
the Australian Red Cross Blood Service in excess 
of one million Australian dollars.17 If CHIKV were 
to become established here with similar seasonal 
outbreaks in the north, it is likely to cause similar 
impacts on blood safety.
There are neither specific treatments for CHIKV nor 
a licensed vaccine. However, some treatments exist 
to relieve symptoms, for example non-steroidal anti-
inflammatory drugs, as well as ribavirin and chloro-
quine.13,58,59 A candidate live-attenuated virus vaccine 
(LAV) based on the wild-type Thai CHIKV strain 
has shown promising results,60 provoking a good 
immune response in humans. In addition, a novel 
CHIK vaccine candidate, called CHIKV/IRES, has 
been developed and also shows promising results.61
Conclusion
This study highlights the main source of CHIKV 
viraemic reported cases and assists risk determination 
which could facilitate the formulation of public health 
policy and ensure the maintenance of the safety of the 
blood supply. The re-emergence of chikungunya in 
Asia and Indian Ocean islands and the emergence 
in the South Pacific regions, with several chikun-
gunya outbreaks in Papua New Guinea, emphasise 
the potential of the virus to cause large outbreaks in 
susceptible populations. Overseas-travel, particularly 
for holidays, is probably the primary mechanism for 
CHIKV introduction to Australia. Therefore, epi-
demiology, human movements, vector biology and 
ecology are all crucial to population health planning 
for potential CHIKV importation into Australia.62
The Australian population is increasingly at risk 
for CHIKV establishment as the number of visitors 
coming from countries endemic for CHIKV and the 
numbers of residents going to visit these countries 
have increased in recent years. This risk will con-
tinue to increase if these countries remain attractive 
and affordable visitor destinations, and if in-country 
control efforts or Australian surveillance and travel-
ler education programs are ineffective. In addition 
to direct morbidity costs, a CHIKV outbreak could 
significantly impact blood supply and tourism.
It would be useful to determine how long people 
stay in the endemic country, for what purpose (work, 
family visit, travel) and obtain information about the 
host (age, sex, income, level of education) and virus 
(strains). Australian authorities must continue to 
implement vector surveillance and control programs 
for the major vectors, Ae. aegypti and Ae. albopictus 
and ensure that the ongoing biosecurity measures 
are maintained in order to keep the country free of 
Ae. albopictus. Media and stakeholders should be kept 
well informed. Greater knowledge of the character-
istics of each imported case is needed. Modeling of 
transmission risk is also important in order to predict 
future vector distribution and disease risk.
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